Alkermes (NASDAQ:ALKS – Get Rating) had its goal value raised by Bank of America from $27.00 to $28.00 in a analysis word issued on Sunday, The Fly stories. Bank of America‘s value goal would counsel a possible upside of three.28% from the corporate’s present value.
ALKS has been the topic of a lot of different analysis stories. JPMorgan Chase & Co. decreased their value goal on shares of Alkermes from $33.00 to $29.00 and set a “impartial” score for the corporate in a report on Tuesday, December sixth. Mizuho raised their value goal on shares of Alkermes from $34.00 to $36.00 and gave the inventory a “purchase” score in a report on Tuesday, November twenty second. Piper Sandler upgraded shares of Alkermes from a “impartial” score to an “chubby” score and raised their value goal for the inventory from $26.00 to $30.00 in a report on Thursday, November third. Lastly, StockNews.com downgraded shares of Alkermes from a “strong-buy” score to a “purchase” score in a analysis word on Wednesday, November 2nd. 4 analysts have rated the inventory with a maintain score and 5 have assigned a purchase score to the inventory. In keeping with knowledge from MarketBeat.com, the inventory presently has a median score of “Reasonable Purchase” and a consensus goal value of $30.10.
Alkermes Inventory Up 7.1 %
Shares of ALKS traded up $1.80 throughout buying and selling hours on Friday, reaching $27.11. 2,177,675 shares of the inventory traded arms, in comparison with its common quantity of 1,148,688. The corporate has a present ratio of two.24, a fast ratio of 1.89 and a debt-to-equity ratio of 0.28. The inventory has a fifty day easy shifting common of $24.68 and a 200 day easy shifting common of $25.27. Alkermes has a 52 week low of $21.75 and a 52 week excessive of $32.79. The corporate has a market cap of $4.45 billion, a price-to-earnings ratio of -34.76 and a beta of 0.57.
Alkermes (NASDAQ:ALKS – Get Rating) final launched its quarterly earnings outcomes on Wednesday, November 2nd. The corporate reported ($0.14) earnings per share for the quarter, lacking analysts’ consensus estimates of ($0.13) by ($0.01). Alkermes had a adverse internet margin of 11.41% and a adverse return on fairness of 1.10%. The agency had income of $252.36 million for the quarter, in comparison with the consensus estimate of $271.45 million. Throughout the identical interval within the earlier yr, the enterprise earned ($0.02) earnings per share. The agency’s income for the quarter was down 14.2% on a year-over-year foundation. On common, equities analysts forecast that Alkermes will publish -0.31 EPS for the present yr.
Hedge Funds Weigh In On Alkermes
A number of hedge funds have just lately purchased and offered shares of the corporate. Vanguard Group Inc. grew its stake in Alkermes by 4.8% in the course of the third quarter. Vanguard Group Inc. now owns 18,107,902 shares of the corporate’s inventory valued at $404,350,000 after buying an extra 828,769 shares within the final quarter. BlackRock Inc. lifted its place in Alkermes by 5.8% in the course of the first quarter. BlackRock Inc. now owns 15,080,046 shares of the corporate’s inventory valued at $396,756,000 after buying an extra 827,759 shares over the last quarter. State Avenue Corp lifted its place in Alkermes by 9.4% in the course of the third quarter. State Avenue Corp now owns 6,467,201 shares of the corporate’s inventory valued at $144,413,000 after buying an extra 556,097 shares over the last quarter. Hardman Johnston International Advisors LLC lifted its place in Alkermes by 7.0% in the course of the third quarter. Hardman Johnston International Advisors LLC now owns 5,734,259 shares of the corporate’s inventory valued at $128,046,000 after buying an extra 376,543 shares over the last quarter. Lastly, Renaissance Applied sciences LLC lifted its place in Alkermes by 4.4% in the course of the third quarter. Renaissance Applied sciences LLC now owns 5,556,113 shares of the corporate’s inventory valued at $124,068,000 after buying an extra 233,500 shares over the last quarter. Hedge funds and different institutional traders personal 96.15% of the corporate’s inventory.
Alkermes Firm Profile
Alkermes plc, a biopharmaceutical firm, researches, develops, and commercializes pharmaceutical merchandise to deal with unmet medical wants of sufferers in numerous therapeutic areas in the USA, Eire, and internationally. Its marketed merchandise embrace ARISTADA, an intramuscular injectable suspension for the therapy of schizophrenia; VIVITROL for the therapy of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the therapy of schizophrenia and bipolar I dysfunction; INVEGA SUSTENNA for the therapy of schizophrenia and schizoaffective dysfunction; XEPLION, INVEGA TRINZA, and TREVICTA to deal with schizophrenia and schizoaffective; and VUMERITY for the therapy of relapsing types of a number of sclerosis in adults, together with clinically remoted syndrome, relapsing-remitting and energetic secondary progressive illnesses.
This prompt information alert was generated by narrative science know-how and monetary knowledge from MarketBeat as a way to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial group previous to publication. Please ship any questions or feedback about this story to firstname.lastname@example.org.
Earlier than you think about Alkermes, you may need to hear this.
MarketBeat retains observe of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they advocate to their shoppers every day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Alkermes wasn’t on the checklist.
Whereas Alkermes presently has a “Reasonable Purchase” score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.